Related Experiment Videos

Hematologic toxicity of sodium valproate

S Acharya1, J B Bussel

  • 1Department of Pediatric Hematology/Oncology, New York Presbyterian Hospital-Cornell Medical Center, New York 10021, USA.

Insights

Sodium valproate can cause hematologic toxicities like bone marrow suppression and bleeding issues. Monitoring and dosage adjustments are key for managing these common side effects in epilepsy patients.

Area of Science:

  • Hematology
  • Pharmacology
  • Pediatric Neurology

Background:

  • Sodium valproate is a widely used anticonvulsant for refractory childhood epilepsy.
  • Hepatotoxicity is a known side effect, but hematologic toxicity is increasingly recognized with higher doses.
  • Pediatric hematologists are often consulted for valproate-induced hematologic issues, especially in pre- or perioperative settings.

Purpose of the Study:

  • To characterize the hematologic toxicities associated with sodium valproate.
  • To provide management guidelines for patients experiencing these toxicities.

Main Methods:

  • A literature review was conducted.
  • Searched for studies on valproate (monotherapy or polytherapy) focusing on hematology and bleeding.

Main Results:

  • Valproate can cause bone marrow suppression, aplastic anemia, and cytopenias (thrombocytopenia, neutropenia, red cell aplasia).
  • Rarely, it may lead to fatal bone marrow failure, myelodysplasia, or acute promyelocytic leukemia-like presentations.
  • A bleeding diathesis can occur due to thrombocytopenia, impaired platelet function, and acquired von Willebrand disease.

Conclusions:

  • Hematologic toxicities are common, variable, and often linked to serum levels >100 microg/mL.
  • Most toxicities are reversible with dose reduction; discontinuation is rare.
  • Lifelong quarterly laboratory monitoring for thrombocytopenia and leukopenia is recommended.
  • Preoperative coagulation studies and potential perioperative DDAVP use are advised for surgical patients.
Abstract

Related Concept Videos